San Diego, CA -- (SBWIRE) -- 08/14/2018 -- An investor, who purchased shares of AbbVie Inc. (NYSE: ABBV), filed a lawsuit over alleged violations of Federal Securities Laws by AbbVie Inc. in connection with certain allegedly false and misleading statements made on May 30, 2018.

Investors, who purchased shares of AbbVie Inc. (NYSE: ABBV), have certain options and for certain investors are short and strict deadlines running. Deadline: September 24, 2018. NYSE: ABBV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of AbbVie Inc. ("AbbVie" or the "Company") (NYSE:ABBV) securities on May 30, 2018 , that the defendants violated Federal Securities Laws.

Before the opening of trading on May 30, 2018, AbbVie Inc announced that it expected to acquire 71.4 million of its shares tendered at or below $105 per share.

As a result of that news, the price of AbbVie Inc. (NYSE: ABBV) securities significantly increased.

However, after the close of trading on May 30, 2018, AbbVie Inc. (NYSE: ABBV) surprised the market by releasing materially different results for the Tender Offer due to certain omissions, announcing that the Company expected to acquire only those shares tendered at or below $103 per share.

The plaintiff claims that the price of the Company's shares fell sharply on the news, harming all investors that purchased AbbVie securities at artificially inflated prices on May 30, 2018.

Those who purchased shares of AbbVie Inc. (NYSE: ABBV) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com